Prevention of Bone Destruction by Mechanical Loading Is Not Enhanced by the Bruton's Tyrosine Kinase Inhibitor CC-292 in Myeloma Bone Disease.
Acrylamides
/ administration & dosage
Agammaglobulinaemia Tyrosine Kinase
/ antagonists & inhibitors
Animals
Bone Diseases
/ etiology
Disease Models, Animal
Humans
Mice
Multiple Myeloma
/ complications
Osteolysis
/ etiology
Protein Kinase Inhibitors
/ administration & dosage
Pyrimidines
/ administration & dosage
Stress, Mechanical
X-Ray Microtomography
Bruton’s tyrosine kinase inhibitor CC-292
bone adaptation
cancer-induced bone disease
mechanical loading
multiple myeloma
skeletal mechanobiology
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
07 Apr 2021
07 Apr 2021
Historique:
received:
08
03
2021
revised:
28
03
2021
accepted:
01
04
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
21
5
2021
Statut:
epublish
Résumé
Limiting bone resorption and regenerating bone tissue are treatment goals in myeloma bone disease (MMBD). Physical stimuli such as mechanical loading prevent bone destruction and enhance bone mass in the MOPC315.BM.Luc model of MMBD. It is unknown whether treatment with the Bruton's tyrosine kinase inhibitor CC-292 (spebrutinib), which regulates osteoclast differentiation and function, augments the anabolic effect of mechanical loading. CC-292 was administered alone and in combination with axial compressive tibial loading in the MOPC315.BM.Luc model for three weeks. However, neither CC-292 alone nor its use in combination with mechanical loading was more effective in reducing osteolytic bone disease or rescuing bone mass than mechanical stimuli alone, as evidenced by microcomputed tomography (microCT) and histomorphometric analysis. Further studies are needed to investigate novel anti-myeloma and anti-resorptive strategies in combination with physical stimuli to improve treatment of MMBD.
Identifiants
pubmed: 33917250
pii: ijms22083840
doi: 10.3390/ijms22083840
pmc: PMC8067978
pii:
doi:
Substances chimiques
Acrylamides
0
Protein Kinase Inhibitors
0
Pyrimidines
0
spebrutinib
DRU6NG543J
Agammaglobulinaemia Tyrosine Kinase
EC 2.7.10.2
BTK protein, human
EC 2.7.10.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Celgene
ID : GRANT-DEU-038
Organisme : Deutsche Forschungsgemeinschaft
ID : JU 426/5-1
Références
Acta Biomater. 2021 Jan 1;119:247-258
pubmed: 33130307
J Orthop Res. 2020 Feb;38(2):233-252
pubmed: 31508836
Cancer Nurs. 2003 Oct;26(5):410-9
pubmed: 14710804
Bone. 2010 Jan;46(1):203-7
pubmed: 19857619
Biomolecules. 2020 Mar 10;10(3):
pubmed: 32164381
J Bone Miner Res. 2009 Mar;24(3):425-36
pubmed: 19016584
J Bone Miner Res. 1995 May;10(5):683-9
pubmed: 7639102
Blood. 2012 Aug 30;120(9):1877-87
pubmed: 22689860
Leukemia. 2008 Dec;22(12):2273-7
pubmed: 18528422
Cancer. 2007 Oct 15;110(8):1860-7
pubmed: 17763372
J Oncol. 2020 Jun 27;2020:3985315
pubmed: 32684931
Mayo Clin Proc. 2003 Jan;78(1):21-33
pubmed: 12528874
Lancet Oncol. 2019 Jun;20(6):e302-e312
pubmed: 31162104
Bone. 2013 Aug;55(2):335-46
pubmed: 23643681
Bone. 2013 May;54(1):113-7
pubmed: 23356987
Front Genet. 2019 Aug 15;10:740
pubmed: 31475039
Sci Rep. 2017 Aug 25;7(1):9435
pubmed: 28842678
Lancet. 2015 May 30;385(9983):2197-208
pubmed: 25540889
Leukemia. 2014 Sep;28(9):1892-901
pubmed: 24518207
BMC Cancer. 2013 Jan 24;13:31
pubmed: 23347597
Int J Cancer. 2019 Jun 1;144(11):2762-2773
pubmed: 30468254
Nat Commun. 2016 May 27;7:11505
pubmed: 27230681
Int J Environ Res Public Health. 2020 Mar 13;17(6):
pubmed: 32183049
Rheumatol Ther. 2020 Mar;7(1):101-119
pubmed: 31721017
Leukemia. 2017 Dec;31(12):2686-2694
pubmed: 28529307
Clin Biomech (Bristol, Avon). 2011 Jan;26(1):101-5
pubmed: 20869796
Bone. 2016 Sep;90:69-79
pubmed: 27262776
Am J Hematol. 2013 Jun;88(6):463-71
pubmed: 23456977
PLoS One. 2012;7(12):e51892
pubmed: 23284805
Blood Cancer J. 2014 Jun 13;4:e217
pubmed: 24927406
Blood. 2017 Jun 29;129(26):3452-3464
pubmed: 28515094
J Biol Chem. 2008 Feb 29;283(9):5866-75
pubmed: 18089564
Cell. 2008 Mar 7;132(5):794-806
pubmed: 18329366
J Bone Miner Res. 2019 Dec;34(12):2311-2326
pubmed: 31442332
Am J Hematol. 2020 May;95(5):548-567
pubmed: 32212178
Arthritis Rheum. 1990 Jan;33(1):66-72
pubmed: 2302269
Haematologica. 2016 Jul;101(7):e295-8
pubmed: 27151992
J Bone Oncol. 2020 Sep 28;25:100323
pubmed: 33083217
Blood. 2019 Apr 4;133(14):1534-1539
pubmed: 30760454